Immunomodulatory drugs and active immunotherapy for chronic lymphocytic leukemia (Q27001318)

Veliz M

series ordinal

2

1 reference

Komrokji R

series ordinal

3

1 reference

Pinilla-Ibarz J

series ordinal

4

1 reference

language of work or name

1 reference

January 2012

1 reference

1 reference

19

1 reference

issue

1

1 reference

page(s)

54-67

1 reference

Intravenous formulations of the enantiomers of thalidomide: pharmacokinetic and initial pharmacodynamic characterization in man.

cites work

1 reference

https://api.crossref.org/works/10.1177%2F107327481201900106

Phase I study to determine the safety, tolerability and immunostimulatory activity of thalidomide analogue CC-5013 in patients with metastatic malignant melanoma and other advanced cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481201900106

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481201900106

Therapeutic renaissance of thalidomide in the treatment of haematological malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481201900106

Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481201900106

Differential secretion of tumor necrosis factor-alpha and granulocyte/macrophage colony-stimulating factors but not interferon-gamma from CD4+ compared to CD8+ human T cell clones

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481201900106

Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481201900106

Efficacy of lenalidomide in myelodysplastic syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481201900106

Amino-substituted thalidomide analogs: potent inhibitors of TNF-alpha production

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481201900106

Structural modifications of thalidomide produce analogs with enhanced tumor necrosis factor inhibitory activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481201900106

Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481201900106

Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481201900106

Immunomodulatory drug costimulates T cells via the B7-CD28 pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481201900106

The anti-cancer agents lenalidomide and pomalidomide inhibit the proliferation and function of T regulatory cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481201900106

Molecular mechanisms whereby immunomodulatory drugs activate natural killer cells: clinical application.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481201900106

Orally administered lenalidomide (CC-5013) is anti-angiogenic in vivo and inhibits endothelial cell migration and Akt phosphorylation in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481201900106

Higher doses of lenalidomide are associated with unacceptable toxicity including life-threatening tumor flare in patients with chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481201900106

Immunomodulating drugs for chronic lymphocytic leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481201900106

Lenalidomide and CC-4047 inhibit the proliferation of malignant B cells while expanding normal CD34+ progenitor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481201900106

Lenalidomide down-regulates the CD20 antigen and antagonizes direct and antibody-dependent cellular cytotoxicity of rituximab on primary chronic lymphocytic leukemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481201900106

Lenalidomide treatment promotes CD154 expression on CLL cells and enhances production of antibodies by normal B cells through a PI3-kinase-dependent pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481201900106

The treatment of advanced renal cell cancer with high-dose oral thalidomide

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481201900106

The role of angiogenesis inhibitors in prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481201900106

Phase II trial of bevacizumab, thalidomide, docetaxel, and prednisone in patients with metastatic castration-resistant prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481201900106

Lenalidomide as initial therapy of elderly patients with chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481201900106

Single-agent lenalidomide in the treatment of previously untreated chronic lymphocytic leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481201900106

Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481201900106

Efficacy of lenalidomide in patients with chronic lymphocytic leukemia with high-risk cytogenetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481201900106

A phase I study of lenalidomide in combination with fludarabine and rituximab in previously untreated CLL/SLL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481201900106

Molecular pathogenesis of chronic lymphocytic leukemia: factors and signaling pathways regulating cell growth and survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481201900106

Fibromodulin as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL), which allows expansion of specific CD8+ autologous T lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481201900106

Fibromodulin, an extracellular matrix protein: characterization of its unique gene and protein expression in B-cell chronic lymphocytic leukemia and mantle cell lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481201900106

MDM2 is recognized as a tumor-associated antigen in chronic lymphocytic leukemia by CD8+ autologous T lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481201900106

Induction of cytotoxic T-cell responses against the oncofetal antigen-immature laminin receptor for the treatment of hematologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481201900106

Induction of adipophilin-specific cytotoxic T lymphocytes using a novel HLA-A2-binding peptide that mediates tumor cell lysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481201900106

Identification of tumor-associated antigens in chronic lymphocytic leukemia by SEREX

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481201900106

B cell chronic lymphocytic leukaemia cells have reduced capacity to upregulate expression of MHC class I in response to interferon-gamma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481201900106

fas-mediated lysis of chronic lymphocytic leukaemia cells: role of type I versus type II cytokines and autologous fasL-expressing T cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481201900106

Acquired CD40-ligand deficiency in chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481201900106

Chronic lymphocytic leukemia cells induce changes in gene expression of CD4 and CD8 T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481201900106

Reduced frequencies and suppressive function of CD4+CD25hi regulatory T cells in patients with chronic lymphocytic leukemia after therapy with fludarabine

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481201900106

Gene therapy and active immune therapy of hematologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481201900106

Autologous antileukemic immune response induced by chronic lymphocytic leukemia B cells expressing the CD40 ligand and interleukin 2 transgenes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481201900106

Molecular transfer of CD40 and OX40 ligands to leukemic human B cells induces expansion of autologous tumor-reactive cytotoxic T lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481201900106

Development of herpes simplex virus-1 amplicon-based immunotherapy for chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481201900106

Rapid and efficient nonviral gene delivery of CD154 to primary chronic lymphocytic leukemia cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481201900106

Help for cytotoxic-T-cell responses is mediated by CD40 signalling.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481201900106

A phase I study of immune gene therapy for patients with CLL using a membrane-stable, humanized CD154

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481201900106

CD154 induces p73 to overcome the resistance to apoptosis of chronic lymphocytic leukemia cells lacking functional p53.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481201900106

Responses to human CD40 ligand/human interleukin-2 autologous cell vaccine in patients with B-cell chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481201900106

Application of interleukin 12 to antitumor cytokine and gene therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481201900106

Combination of CD80 and granulocyte-macrophage colony-stimulating factor coexpression by a leukemia cell vaccine: preclinical studies in a murine model recapitulating Philadelphia chromosome-positive acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481201900106

Gene transfer of GM-CSF, CD80 and CD154 cDNA enhances survival in a murine model of acute leukemia with persistence of a minimal residual disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481201900106

Potential approach to immunotherapy of chronic lymphocytic leukemia (CLL): enhanced immunogenicity of CLL cells via infection with vectors encoding for multiple costimulatory molecules

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481201900106

Chronic lymphocytic leukemia (CLL) cells genetically modified to express B7-1, ICAM-1, and LFA-3 confer APC capacity to T cells from CLL patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481201900106

The first 1000 dendritic cell vaccinees.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481201900106

Induction of chronic lymphocytic leukemia (CLL)–specific CD4- and CD8-mediated T-cell responses using RNA-transfected dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481201900106

Leukemia-associated monoclonal and oligoclonal TCR-BV use in patients with B-cell chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481201900106

Development of a dendritic cell-based vaccine for chronic lymphocytic leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481201900106

Dendritic cells loaded with apoptotic tumour cells induce a stronger T-cell response than dendritic cell-tumour hybrids in B-CLL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481201900106

Allogeneic dendritic cells pulsed with tumor lysates or apoptotic bodies as immunotherapy for patients with early-stage B-cell chronic lymphocytic leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481201900106

Vaccination of B-CLL patients with autologous dendritic cells can change the frequency of leukemia antigen-specific CD8+ T cells as well as CD4+CD25+FoxP3+ regulatory T cells toward an antileukemia response.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481201900106

A polyvalent cellular vaccine induces T-cell responses against specific self-antigens overexpressed in chronic lymphocytic B-cell leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481201900106

A phase I/II trial of oxidized autologous tumor vaccines during the "watch and wait" phase of chronic lymphocytic leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481201900106

Identification and characterization of epitopes of the receptor for hyaluronic acid-mediated motility (RHAMM/CD168) recognized by CD8+ T cells of HLA-A2-positive patients with acute myeloid leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481201900106

Receptor for hyaluronan acid-mediated motility (RHAMM) is a new immunogenic leukemia-associated antigen in acute and chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481201900106

Characterization of several leukemia-associated antigens inducing humoral immune responses in acute and chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481201900106

Increased expression of CD152 (CTLA-4) by normal T lymphocytes in untreated patients with B-cell chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481201900106

Immunoglobulin framework-derived peptides function as cytotoxic T-cell epitopes commonly expressed in B-cell malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481201900106

Survivin is expressed on CD40 stimulation and interfaces proliferation and apoptosis in B-cell chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481201900106